S&P 500 Medical Stocks: Three Trade Near Buy Points; One Rallies Despite Mixed Results

S&P 500 drug distributor Cardinal Health easily topped fiscal fourth-quarter earnings forecasts despite a revenue shortfall. Rival McKesson, which whipsawed after its earnings report last week, has climbed back near a buy point. Cencora, another big S&P 500 drug distributor, also is near a buy point, but MCK stock may be the strongest of the three.